Recombinant Human Growth Hormone in Refractory Erectile Dysfunction with Low Insulin-like Growth Factor-1
Objective To observe clinical efficacy of recombinant human growth hormone in the treatment of patients with refractory penile erectile dysfunction(ED)accompanied with low insulin-like growth factor-1(IGF-1).Methods A total of 19 patients with refractory ED with low IGF-1,aged from 25 to 65 years,were selected from the Urology and Andrology Outpatients of our hospital from June 2022 to February 2023.All the subjects were injected with recombinant hu-man growth hormone(2U,subcutaneously into the abdominal wall at bedtime,once a week on Mondays and Thursdays).The International Index of Erectile Function Questionnaire 5(IIEF-5)scores,Questions 2 and 3 in the Sexual Life Log(SEP)were recorded before treatment,at months 1 and 3 of treatment,respectively.Patients were also monitored for changes in liver and kidney functions,blood glucose,blood lipid,testosterone,IGF-1,and prostate-specific antigen(PSA)be-fore treatment and in the 3rd month of treatment,and adverse reactions that occurred during treatment were recorded.Results All the 19 patients enrolled in the study completed follow-up visits.The IIEF-5 scores at the 3rd month of treatment were 11.63±2.81,higher than the pre-treatment scores(7.53±2.75)(P＜0.05);the overall response rate at the 3rd month of treatment was 68.4％(13/19).The answers"yes"to SEP2/3 were 0％before treatment,15.8％/5.3％after 1 month and 42.1％/26.3％after 3 months.The blood index IGF-1 after treatment was higher than that before treatment(P＜0.05),and the difference of other related indexes was not statisti-cally significant(P＞0.05).During the treatment,the incidence rate of adverse reactions was 21.1％(4/19),which were all alleviated on their own without special interventions.Conclusion Recombinant human growth hormone can alleviate clinical symptoms and bring a favorable re-sponse rate in patients with refractory ED with low IGF-1.
NETL
NSTL
万方数据
